glp-1 gip gcg LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Mechanisms of GLP-1 Receptor Agonist-Induced

GLP-1 is both anxiogenic and antidepressant

In line with these principles, the guidelines advocate weight management as the primary approach, followed by carbonic anhydrase inhibitors such as acetazolamide, which lower ICP by inhibiting CSF production and further relieving the symptoms of elevated ICP [13-15]

6870 However, in patients with cirrhotic conditions (fibrosis stage 4), there is no difference in MASH regression compared to placebo treatment after SEMA 2.4 mg weekly

Their long-term risk profile is still unknown

References: Elective perioperative management of adults taking glucagonlike peptide1 receptor agonists, glucosedependent insulinotropic peptide agonists and sodiumglucose cotransporter2 inhibitors: A multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association

In the United States, the Centers for Disease Control and Prevention (CDC) reports that over 38.4 million individuals, approximately 11.6% of the population, are currently living with diabetes [2]